|1.||Zapata-Sudo, Gisele: 2 articles (01/2014 - 11/2010)|
|2.||Caruso-Neves, Celso: 2 articles (01/2014 - 11/2010)|
|3.||Barreiro, Eliezer Jesus: 1 article (01/2014)|
|4.||Fraga, Carlos Alberto Manssour: 1 article (01/2014)|
|5.||Landgraf, Sharon Schilling: 1 article (01/2014)|
|6.||Maia, Rodolfo do Couto: 1 article (01/2014)|
|7.||Sudo, Roberto Takashi: 1 article (01/2014)|
|8.||Kümmerle, Arthur Eugen: 1 article (01/2014)|
|9.||da Silva, Jaqueline Soares: 1 article (01/2014)|
|10.||Pereira, Sharlene Lopes: 1 article (01/2014)|
11/01/2001 - "In addition, LASSBio-294 reduced development of fatigue induced by tetanic stimulation of the muscle fibers and reduced the time needed for 80% prefatigue tension recovery after fatigue had developed to 50% of the maximal pretetanic force. "
11/01/2001 - "This study was designed to investigate the effects on single skeletal muscle fibers of a novel thienylhydrazone, referred to as LASSBio-294, which is a bioisoster of pyridazinone compounds that inhibit the cyclic AMP-specific phosphodiesterase (PDE) 4. Twitch and fatigue were analyzed in single skeletal muscle fibers isolated from either the semitendinous or the tibialis anterior muscles dissected from the frog Rana pipiens. "
01/14/2014 - "In MI rats treated with LASSBio-294, the time to fatigue was 15.1 ± 3.6 min. During the contractile test, SOL muscles from sham rats showed a response of 7.12 ± 0.54N/cm(2) at 60 Hz, which was decreased to 5.45 ± 0.49 N/cm(2) (P<0.05) in MI rats. "
11/01/2010 - "LASSBio-294 is a promising candidate for improving intracellular Ca²(+) regulation and preventing MI-induced cardiac dysfunction, which could potentially prevent heart failure (HF)."
11/01/2001 - "The novel thienylhydrazone LASSBio-294 may be useful for treatment of patients suffering from conditions in which muscle fatigue is a debilitating symptom (e.g., chronic heart failure)."
|4.||Cardiomegaly (Heart Hypertrophy)
|1.||Cyclic AMP (AMP, Cyclic)
|2.||Polymethyl Methacrylate (Sol)
|3.||salicylhydroxamic acid (SHAM)